Schrödinger (SDGR) Q1 2026: Hosted Software Share Jumps to 34% as Agentic AI Launch Nears
Hosted licensing accelerated to 34% of software revenue, signaling a pivotal shift in Schrödinger’s business model. The company’s agentic AI “Bunsen” is set for early access this summer, with management emphasizing both internal productivity gains and broad customer interest. With drug discovery revenue buoyed by collaboration milestones and a robust balance sheet, the focus is on scaling platform adoption and monetizing computational breakthroughs.
Summary
- Hosted Transition Gains Ground: Hosted software now at 34% of segment revenue, with early conversions ahead of renewals.
- Agentic AI Rollout Catalyzes Demand: Bunsen’s launch expected to expand user base and drive throughput-based licensing.
- Collaboration Model Validated: Multi-billion dollar Ajax exit and pipeline milestones reinforce the platform’s commercial leverage.
Business Overview
Schrödinger delivers computational software and collaborative drug discovery services for the life sciences and materials industries. The core business model blends physics-based simulation software, sold via recurring licenses, with drug discovery partnerships and equity stakes in co-founded biotech ventures. Major revenue streams include software licensing (now rapidly shifting to hosted/cloud delivery), drug discovery milestones, and collaborative equity returns.
Performance Analysis
Annual Contract Value (ACV) rose 12% year-over-year, driven by broad-based adoption among top 20 pharma customers, new product uptake, and expansion of the hosted licensing model. Hosted software contributed 34% of segment revenue, up from 24% a year ago, marking a rapid acceleration in the transition away from on-premise deployments. Management reported early conversions of multi-year on-premise contracts to hosted, providing incremental tailwinds to recurring revenue visibility.
Drug discovery revenue more than doubled year-over-year, reflecting accelerated recognition of deferred revenue and the wind-down of a collaboration program. However, contribution revenue dropped sharply due to the completion of Gates Foundation funding for predictive toxicology, clarifying the impact of non-commercial sources on prior period comparisons. Operating expenses declined 4% year-over-year, a result of efficiency measures and disciplined R&D and G&A management, though investment in sales and marketing continued to support new product launches.
- Hosted Licensing Surge: Hosted software now represents over a third of segment revenue, with a stated goal of 75% within three years.
- Drug Discovery Upside: Ajax Therapeutics exit and ongoing pipeline milestones highlight the value of the collaboration model.
- Margin Compression: Software gross margin fell to 69% from 80% due to hosted transition, but this is expected to stabilize as the mix normalizes.
The company ended the quarter with $406 million in cash and marketable securities, positioning it to sustain investment and weather variability in drug discovery revenue tied to milestone timing.
Executive Commentary
"Our market-leading position is built on the inherent accuracy and scalability of our physics-based approach and is further reinforced by our unmatched track record. While standard AI models are limited by the scarcity of training data, our platform generates the ground truth simulations, accuracy and scale required for AI to precisely navigate the vastness of chemical space."
Rami Fareed, Chief Executive Officer
"ACV growth was primarily driven by our top 20 pharma customers, these customers broaden their platform access, onboard new products and integrate our platform more deeply into their R&D organizations. Starting this quarter, we are breaking out contribution revenue as a separate line item to provide better visibility into our software and drug discovery performance."
Richie Jane, Chief Financial Officer
Strategic Positioning
1. Hosted Licensing Model Transformation
Schrödinger is rapidly migrating customers from on-premise to hosted (cloud-based) software licenses, which shifts revenue recognition to a ratable model and increases recurring visibility. Early conversions ahead of scheduled renewals and 100% hosted deployment for new customers underscore customer acceptance and operational readiness. The company targets 75% hosted mix within three years, a move expected to stabilize financials and align revenue with actual platform usage.
2. Agentic AI “Bunsen” as a Platform Multiplier
Bunsen, an agentic AI co-scientist, is set for early access launch this summer, with internal usage already producing “extraordinary” productivity gains. The solution is designed to democratize advanced computational workflows, lowering the expertise barrier for molecular discovery. Management expects Bunsen to both deepen adoption among existing users and unlock new customer segments, with its impact monetized through throughput-based licensing rather than seat-based contracts.
3. Collaboration-Driven Value Creation
The Ajax Therapeutics $2.3 billion acquisition by Lilly, with Schrödinger holding a 6% equity stake, validates the company’s co-development model. Seven major liquidity events have now been realized across the biotech portfolio, generating close to $700 million in cash and positioning the company for up to $5 billion in future milestones and royalties on 15 programs. This diversified exposure provides both near-term revenue and long-term optionality.
4. Predictive Toxicology and Regulatory Tailwinds
The predictive toxicology initiative is positioned to capitalize on FDA’s push to reduce animal testing, with early customer feedback and pilot results described as “very, very positive.” While contribution revenue from Gates Foundation funding has wound down, the commercial opportunity for computational toxicology is just beginning to unfold, potentially creating a new growth vector as adoption spreads.
5. Operating Discipline Amid Expansion
Operating expenses fell 4% year-over-year, reflecting management’s commitment to efficiency even as sales and marketing investments rise to support new product launches and hosted adoption. The company is winding down internal clinical activities and prioritizing partnerships for mid- and late-stage development, focusing R&D spend on collaborative and high-leverage opportunities.
Key Considerations
This quarter marks a clear inflection in Schrödinger’s business model, as recurring hosted revenue and platform-based licensing take center stage. The company’s execution on both technology and commercial fronts is driving a transition that will define its financial profile for years to come.
Key Considerations:
- Hosted Migration Pace: Accelerated hosted adoption is smoothing revenue streams but temporarily compressing gross margins.
- Agentic AI Monetization: Bunsen’s success hinges on both expert and non-expert uptake, with pricing and go-to-market strategy still evolving.
- Milestone-Driven Drug Discovery: Revenue variability remains tied to collaboration milestones and equity events, which can be lumpy quarter to quarter.
- Equity and Cash Leverage: The Ajax exit bolsters the balance sheet and provides strategic flexibility for future investment or partnership expansion.
- Expense Management: Ongoing discipline in R&D and G&A spend supports the path to profitability, especially as internal clinical development winds down.
Risks
Revenue visibility is improving via hosted licensing, but milestone-driven drug discovery remains inherently volatile, with timing of major transactions outside management’s direct control. The shift to hosted compresses margins in the near term and requires continued customer migration. Regulatory changes, while a tailwind for computational toxicology, also introduce uncertainty around adoption rates and competitive responses. Execution risk remains high around the agentic AI rollout, especially in pricing and integration with diverse customer workflows.
Forward Outlook
For Q2 2026, Schrödinger guided to:
- ACV of $19 to $23 million, excluding contribution ACV
- Drug discovery revenue of $55 to $65 million for the full year
For full-year 2026, management maintained guidance:
- ACV of $218 to $228 million, representing 10% to 15% growth
- Operating expenses to be less than 2025, with continued investment in sales and marketing
Management highlighted several factors that will shape the year:
- Continued acceleration in hosted migration and expansion of throughput-based licensing
- Potential upside from new collaborations and equity events, though not explicitly included in guidance
Takeaways
Schrödinger’s transition to hosted software and throughput-based licensing is reshaping its revenue model, providing greater predictability but requiring near-term margin trade-offs. The upcoming Bunsen AI launch is a strategic bet on democratizing advanced computational workflows, with success dependent on both technical execution and commercial adoption.
- Hosted Model Inflection: The rapid increase in hosted revenue share is foundational to recurring revenue growth and business model resilience.
- Collaboration Portfolio Leverage: Multi-billion dollar exits and a robust pipeline of milestones and royalties provide asymmetric upside.
- Platform Monetization Watchpoint: Investors should monitor Bunsen’s rollout, hosted conversion velocity, and the translation of R&D investments into scalable, recurring revenue streams.
Conclusion
Schrödinger’s Q1 2026 results underscore a business in the midst of a strategic transformation, with hosted licensing, AI-driven product launches, and collaboration economics defining the next phase. The company’s execution on these fronts, coupled with disciplined expense management, positions it to capitalize on both recurring software and milestone-driven discovery revenue.
Industry Read-Through
Schrödinger’s hosted migration and agentic AI launch signal a broader shift in scientific software toward cloud-first, usage-based models—a trend likely to extend across computational chemistry, life sciences informatics, and adjacent verticals. The success of co-developed molecules and multi-billion dollar exits validates the power of computational R&D partnerships, setting a template for other platform companies seeking to monetize both software and discovery economics. Regulatory momentum for computational toxicology may unlock new markets, but also raises the bar for accuracy and validation, favoring platforms with proven track records and deep integration capability.